AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC

18 Jan 2017

• By Sukaina Virji

With tensions rising in the first-line NSCLC space, AstraZeneca's update on the analysis plan of its Phase III MYSTIC trial has analysts reassessing the firm’s chances against stiff competition.

AstraZeneca PLC's revisions to its MYSTIC trial evaluating its anti-PD-L1 durvalumab and anti-CTLA-4 tremelimumab in first-line non-small cell lung cancer (NSCLC) should expand the scope of what is possible with the trial, but it now runs the risk of being underpowered.

The new plan places slightly more emphasis on durvalumab as a monotherapy, despite AstraZeneca stating: "the focus remains on exploring...